How much will the IRA Medicare pricing cut hurt BMY's Eliquis revenue?

Eliquis was among the first ten drugs selected for Medicare price negotiation under the IRA. Negotiated prices apply starting 2026. The actual reduction in BMY's net Eliquis revenue depends on the negotiated price and the Medicare-to-commercial mix. Current figures should be verified in BMY's 10-Q filings at sec.gov or bms.com/investors.

What is Cobenfy and why does it matter for BMY's growth story?

Cobenfy (KarXT) is BMY's FDA-approved schizophrenia treatment acquired through the $14B Karuna deal. It targets muscarinic acetylcholine receptors (M1/M4) rather than dopamine D2, giving it a differentiated side-effect profile. Its long-term significance depends on commercial penetration in schizophrenia and whether the Alzheimer's psychosis indication succeeds in trials.

Is BMY's dividend safe given all the M&A debt?

BMY has signaled commitment to its dividend, but the combination of Eliquis IRA headwind, Karuna ($14B) + RayzeBio ($4.1B) + Mirati ($4.8B) debt load, and Opdivo competitive pressure means free cash flow is under scrutiny. Check the latest payout ratio and FCF guidance at bms.com/investors.

How does BMY compare to ABBV and PFE for 2026?

ABBV has largely cleared its patent cliff with Skyrizi/Rinvoq growth. PFE faces post-COVID normalization and is executing its own M&A strategy. BMY sits in the middle: larger M&A integration risk than ABBV, but with a potentially higher upside if Cobenfy and radiopharma hits. All three are verifiable at their respective IR pages.

Bristol-Myers Squibb (BMY) Stock Outlook 2026: IRA Pricin...

Bristol-Myers Squibb is in the middle of one of the most aggressive transformation bets in large-cap pharma. Between 2023 and 2024, the company deployed roughly $23 billion across three acquisitions — Karuna Therapeutics, RayzeBio, and Mirati Therapeutics — while simultaneously absorbing the first major blow from IRA Medicare drug pricing negotiations on its top revenue drug, Eliquis. The investment thesis in 2026 is essentially a wager on whether the M&A integration generates enough growth to outpace the Eliquis headwind and the interest burden that comes with it.

Eliquis IRA: Pricing Headwind Quantified at BMY’s IR, Not Here

Eliquis (apixaban) has been BMY’s single largest revenue contributor, co-marketed with Pfizer. The drug’s role in atrial fibrillation stroke prevention and VTE treatment made it one of the most prescribed anticoagulants globally.

Under the 2022 Inflation Reduction Act, Eliquis was selected in the first batch of ten drugs subject to direct Medicare price negotiation. Negotiated prices began applying in 2026.

The critical caveat: BMY books approximately half of global Eliquis profits, with Pfizer booking the other half. So the IRA pricing impact on BMY’s reported revenue is not the same as the headline Eliquis revenue cut. The exact share split and net revenue impact are disclosed in BMY’s quarterly filings — the 10-Q from SEC EDGAR is the only reliable source. Any specific revenue estimate here would be speculation.

What is clear: Eliquis as a growth engine is over. The question is how fast it declines and whether the replacement pipeline outpaces the decline.

Related: Global Dividend Stocks Guide 2026 →

Karuna / Cobenfy: The $14B CNS Bet

In early 2024, BMY acquired Karuna Therapeutics for approximately $14 billion — the company’s largest acquisition since Celgene in 2019. The primary asset: KarXT, now branded Cobenfy, which received FDA approval for schizophrenia in September 2024.

Why Cobenfy’s mechanism matters

Every approved schizophrenia drug before Cobenfy worked by blocking dopamine D2 receptors — a mechanism from the 1950s. The associated side effects (extrapyramidal symptoms, metabolic effects, weight gain) are well-known and a reason patients discontinue therapy.

Cobenfy targets muscarinic M1/M4 acetylcholine receptors, a mechanistically novel approach. Phase 3 data showed efficacy on both positive symptoms and potentially negative symptoms (motivation, social withdrawal) — the latter being an area where D2 blockers have historically underperformed.

The commercial ramp question

FDA approval is step one. Commercial penetration in CNS is typically slow: psychiatrists are conservative prescribers, payer coverage negotiations take time, and schizophrenia is a complex patient population. BMY is building out a dedicated CNS sales force, but the time horizon to meaningful Cobenfy revenue is measured in years, not quarters.

The Alzheimer’s psychosis indication is in late-stage trials. If approved, it would expand the addressable market significantly. That outcome should be tracked through BMY’s pipeline page, not priced in as a given.

RayzeBio: The Radiopharma Platform Entry at $4.1B

BMY paid approximately $4.1 billion for RayzeBio, a company building targeted radiopharmaceutical therapies (TRT). The concept: attach a radioactive isotope to a cancer-targeting molecule, delivering precision radiation at the tumor while limiting systemic exposure.

Novartis validated the commercial model with Lutathera (neuroendocrine tumors) and Pluvicto (prostate cancer). The market has since attracted Eli Lilly (Point Biopharma acquisition) and Lantheus, making this a competitive space.

RayzeBio’s pipeline is earlier-stage than the validated Novartis assets. The strategic value is platform and manufacturing capability rather than near-term revenue. BMY’s radiopharma thesis plays out over a 5–10 year horizon. Current pipeline status is best tracked at bms.com/investors under R&D pipeline.

Mirati / Krazati: The KRAS G12C Contest

BMY’s acquisition of Mirati Therapeutics for approximately $4.8 billion brought in Krazati (adagrasib), a KRAS G12C inhibitor approved for non-small cell lung cancer.

KRAS G12C mutations drive approximately 13% of NSCLC cases — a meaningful patient population. Amgen’s Lumakras (sotorasib) was first to market, and the clinical debate between the two agents centers on efficacy, tolerability, and combination regimens.

Krazati’s differentiation angle includes CNS penetration data that may be relevant for patients with brain metastases. Expansion into colorectal cancer (another KRAS-driven tumor) and combination trials with PD-1 inhibitors are ongoing. This competitive landscape requires ongoing monitoring — neither drug has definitively won.

Opdivo Franchise: Maintaining Value in a Keytruda World

Opdivo (nivolumab) was a PD-1 pioneer. In 2026, the frank assessment is that Merck’s Keytruda (pembrolizumab) has captured first-line lung cancer and several other key indications where Opdivo had hoped to lead. The gap is real.

BMY’s counter-strategy is combination depth:

Opdivo + Yervoy (ipilimumab, CTLA-4): Dual checkpoint in renal cell carcinoma and NSCLC
Opdualag (nivolumab + relatlimab, LAG-3): Fixed-dose combination in melanoma with PFS improvement over Opdivo monotherapy; LAG-3 is the most validated next-generation checkpoint after PD-1/CTLA-4

Opdualag’s expansion potential across tumor types could sustain the franchise even as individual Opdivo-only indications face Keytruda competition. Watch FDA decisions on new Opdualag indications.

Reblozyl and Camzyos: Underappreciated Revenue Engines

Two assets acquired through the 2021 Acceleron Pharma deal ($11.1B) deserve attention:

Reblozyl (luspatercept): Erythroid maturation agent approved in beta-thalassemia and MDS. Growing prescription volumes as the drug continues to expand into first-line MDS positioning.
Camzyos (mavacamten): The first-in-class myosin inhibitor for hypertrophic cardiomyopathy (HCM), both obstructive and non-obstructive forms. A rare cardiovascular niche with limited competition, growing steadily.

Neither replaces Eliquis at scale, but both add meaningful diversification and face lower competitive pressure than the oncology franchise.

M&A Integration ROIC: The Math That Matters

BMY has spent roughly $23B on three acquisitions in roughly 18 months. The return on invested capital (ROIC) question is the most important financial judgment for BMY:

Karuna ($14B): ROIC depends on Cobenfy’s commercial trajectory in schizophrenia and Alzheimer’s psychosis approval. This is a long-duration asset.
RayzeBio ($4.1B): ROIC is speculative at this stage; clinical and commercial success is years out.
Mirati ($4.8B): ROIC depends on Krazati’s competitive position vs. Lumakras and combination regimen uptake.

The carrying debt and interest expense from these deals is a real drag on near-term FCF. BMY’s ability to sustain the dividend, maintain R&D spending, and not do a dilutive equity raise all depend on how quickly these assets generate cash. Verify current net debt and coverage ratios in the latest 10-Q at SEC EDGAR.

Related: ABBV AbbVie Dividend Analysis 2026 →

Patent Cliff Math: Beyond Eliquis

The Eliquis IRA story gets the headlines, but BMY’s longer-term patent exposure includes Opdivo (patents beginning to expire in late 2020s in some markets) and legacy Revlimid (lenalidomide, acquired via Celgene). Revlimid generic erosion was a known risk that began materializing from 2022 — its contribution to current revenue should be checked in recent filings, as it has been declining.

BMY’s patent cliff arithmetic is more complex than ABBV’s because the assets are spread across multiple therapeutic areas and geographies, each with different biosimilar/generic timelines.

Dividend Sustainability: FCF Watch

BMY has maintained and grown its dividend through previous periods of transition. The current quarterly dividend is disclosed at bms.com/investors — it is not repeated here to avoid stale data.

The sustainability question in 2026:

Payout ratio relative to adjusted EPS (check latest earnings release)
FCF after capex, R&D, and debt service — this is what actually funds the dividend
Share buybacks have been minimal given debt levels; this is consistent with capital preservation but matters for EPS growth

If Eliquis deteriorates faster than Cobenfy/Camzyos/Reblozyl ramp, FCF could compress. Management guidance on FCF is the most important number to watch at each quarterly earnings call.

Bull and Bear Cases

Bull case

Cobenfy achieves strong commercial uptake; Alzheimer’s psychosis indication approved
Krazati gains significant share in KRAS G12C NSCLC; colorectal data positive
RayzeBio phase 2 readouts show clinical differentiation
Eliquis IRA hit is smaller than feared due to Pfizer co-economics and Medicare mix
Camzyos and Reblozyl continue double-digit volume growth

Bear case

Eliquis Medicare price cuts are severe and immediate; BMY’s portion shrinks faster than expected
Cobenfy commercial ramp is slow; psychiatry prescribing patterns resist change
M&A integration costs and debt burden compress FCF below dividend coverage
Opdivo loses additional major indications to Keytruda or emerging PD-L1 competitors

Where to Verify Before Investing

BMY Investor Relations: bms.com/investors
SEC EDGAR filings (10-K, 10-Q): sec.gov
FDA Oncology approvals and pipeline: fda.gov/about-fda/oncology-center-excellence
IRA Medicare negotiated drug prices: cms.gov/inflation-reduction-act

This article is informational only and does not constitute investment advice. All investment decisions should be made based on your own research and judgment.